60 Degrees Pharmaceuticals (SXTP) & Its Competitors Critical Review

60 Degrees Pharmaceuticals (NASDAQ:SXTP) is one of 1,004 public companies in the “Pharmaceutical preparations” industry, but how does it contrast to its peers? We will compare 60 Degrees Pharmaceuticals to similar companies based on the strength of its analyst recommendations, dividends, institutional ownership, profitability, earnings, valuation and risk.

Profitability

This table compares 60 Degrees Pharmaceuticals and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
60 Degrees Pharmaceuticals	N/A	N/A	-78.95%
60 Degrees Pharmaceuticals Competitors	-2,992.57%	-287.70%	-33.64%

Insider & Institutional Ownership

8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. Comparatively, 44.5% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 10.3% of 60 Degrees Pharmaceuticals shares are owned by insiders. Comparatively, 13.9% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of recent recommendations for 60 Degrees Pharmaceuticals and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
60 Degrees Pharmaceuticals	0	1	1	0	2.50
60 Degrees Pharmaceuticals Competitors	6701	19249	45708	970	2.56

60 Degrees Pharmaceuticals currently has a consensus target price of $2.40, suggesting a potential upside of 848.99%. As a group, “Pharmaceutical preparations” companies have a potential upside of 74.88%. Given 60 Degrees Pharmaceuticals’ higher possible upside, equities analysts clearly believe 60 Degrees Pharmaceuticals is more favorable than its peers.

Valuation and Earnings

This table compares 60 Degrees Pharmaceuticals and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
60 Degrees Pharmaceuticals	$352,864.00	-$3.77 million	-0.24
60 Degrees Pharmaceuticals Competitors	$1.68 billion	$153.43 million	-2.98

60 Degrees Pharmaceuticals’ peers have higher revenue and earnings than 60 Degrees Pharmaceuticals. 60 Degrees Pharmaceuticals is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Summary

60 Degrees Pharmaceuticals peers beat 60 Degrees Pharmaceuticals on 8 of the 12 factors compared.

About 60 Degrees Pharmaceuticals

60 Degrees Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue. 60 Degrees Pharmaceuticals, Inc. was founded in 2010 and is based in Washington, District Of Columbia.